Supernus Pharmaceuticals (NASDAQ:SUPN) Hits New 12-Month Low - What's Next?

Key Points

• Supernus Pharmaceuticals shares fell to a new 52-week low of $41.05, down 1.4%, with the stock trading below its 50-day and 200-day moving averages.
• Analyst sentiment is mixed, resulting in a consensus “Hold” rating and an average price target of $62.83; recent actions included a Cantor Fitzgerald target increase and rating downgrades from Zacks Research and Wall Street Zen.
• The company’s latest quarter showed strong revenue growth of 32.4% year over year to $219.1 million, but it reported a $1.01 per-share loss, substantially missing the $0.42 consensus estimate.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) shares hit a new 52-week low on Tuesday . The company traded as low as $41.05 and last traded at $41.16, with a volume of 61717 shares trading hands. The stock had previously closed at $41.49.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on SUPN shares. Cantor Fitzgerald raised their price target on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an "overweight" rating in a research note on Thursday, July 9th. Zacks Research cut Supernus Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Friday, September 4th. Weiss Ratings reissued a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Finally, Wall Street Zen cut Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $62.83.

Supernus Pharmaceuticals Trading Down 1.4%

The firm has a 50 day moving average price of $46.07 and a 200 day moving average price of $48.01. The stock has a market capitalization of $2.38 billion, a PE ratio of -21.30, a price-to-earnings-growth ratio of 0.77 and a beta of 0.56.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last released its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of $0.42 by ($1.43). The company had revenue of $219.06 million for the quarter, compared to analysts' expectations of $205.31 million. Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. Supernus Pharmaceuticals's revenue for the quarter was up 32.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.40 earnings per share. On average, equities research analysts expect that Supernus Pharmaceuticals, Inc. will post 1.97 EPS for the current year.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SUPN. Public Employees Retirement System of Ohio purchased a new position in shares of Supernus Pharmaceuticals during the second quarter valued at about $25,000. Rockefeller Capital Management L.P. lifted its position in shares of Supernus Pharmaceuticals by 354.8% in the fourth quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company's stock worth $42,000 after buying an additional 660 shares in the last quarter. Hantz Financial Services Inc. lifted its position in shares of Supernus Pharmaceuticals by 73.3% in the fourth quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company's stock worth $54,000 after buying an additional 458 shares in the last quarter. Global Retirement Partners LLC bought a new position in Supernus Pharmaceuticals during the second quarter valued at approximately $64,000. Finally, Nykredit A S bought a new position in Supernus Pharmaceuticals during the second quarter valued at approximately $110,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) disorders. The company's portfolio addresses conditions including epilepsy, migraine and attention-deficit/hyperactivity disorder (ADHD), with an emphasis on extended-release and other drug-delivery technologies.

Supernus markets Oxtellar XR (oxcarbazepine extended-release) for the treatment of partial-onset seizures and Trokendi XR (topiramate extended-release) for certain epilepsy indications and the prevention of migraine headaches.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.